Detalles de la búsqueda
1.
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Eur Heart J
; 43(6): 474-484, 2022 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35023547
2.
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Nephrol Dial Transplant
; 37(6): 1014-1023, 2022 05 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33280027
3.
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis.
Ann Intern Med
; 174(10): 1420-1429, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34516270
4.
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.
Br J Haematol
; 183(3): 457-465, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30123981
5.
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Blood
; 127(11): 1417-25, 2016 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26696010
6.
Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.
Pharm Stat
; 15(4): 324-32, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25981683
7.
Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.
Thromb J
; 12: 26, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25698905
8.
A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry.
Ther Innov Regul Sci
; 2024 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649524
9.
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.
J Am Coll Cardiol
; 83(6): 669-678, 2024 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325992
10.
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
JAMA Cardiol
; 8(8): 732-741, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314801
11.
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Eur Heart J Cardiovasc Pharmacother
; 9(2): 183-191, 2023 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36639130
12.
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
Clin Kidney J
; 16(2): 293-302, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36864892
13.
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
J Thromb Haemost
; 20(6): 1376-1384, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35253983
14.
Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study.
Vasc Specialist Int
; 38: 33, 2022 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36573027
15.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Diabetes Care
; 45(12): 2991-2998, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972218
16.
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
Res Pract Thromb Haemost
; 5(3): 426-438, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33870028
17.
Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.
J Thromb Haemost
; 19(11): 2801-2813, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34379859
18.
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
Eur J Intern Med
; 61: 29-33, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30342973
19.
Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA.
TH Open
; 3(1): e85-e93, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31249987
20.
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
Thromb Res
; 176: 125-132, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30825694